Cochrane Review Finds No Clear Sleep Benefit From Medical Cannabis
A review of nine trials finds uncertain sleep benefits from medical cannabis and more adverse events, challenging its use for insomnia.
Summary
Medical cannabis has become a popular option for insomnia, but this Cochrane review found no clear evidence that it meaningfully improves sleep. Researchers analyzed nine randomized studies involving 537 adults, mostly women. Compared with placebo, cannabis showed uncertain effects on sleep quality, sleep duration, and daytime functioning. The estimated increase in sleep time was about eight minutes, but the results were compatible with either shorter or longer sleep. Possible improvements in quality of life were also uncertain. Adverse events were more likely with cannabis, although evidence for this finding was limited. Differences between treatments, small studies, and study weaknesses make firm conclusions difficult. For patients and clinicians, the takeaway is caution: cannabis is not an established insomnia treatment based on this evidence. This summary is based on the abstract only.
Detailed Summary
Insomnia can undermine daytime functioning and quality of life, making effective sleep treatments important for healthy aging. Medical cannabis is increasingly used for sleep problems, but popularity does not establish benefit. This Cochrane review examined whether cannabis treatments improve insomnia and whether any improvements outweigh adverse effects in adults. It did not test effects on aging or lifespan directly.
Researchers combined nine randomized studies involving 537 adults aged 18 to 76 years. Approximately 73 percent were women. Six studies addressed chronic insomnia and three addressed acute insomnia. Eight compared cannabis with placebo; one used amitriptyline as the comparator. Treatments included two licensed medications and seven compounded preparations. Searches covered multiple major databases and trial registers through April 5, 2025.
Compared with placebo, cannabis did not show a clear, clinically meaningful improvement in sleep quality, total sleep time, or daytime functioning. The estimated increase in sleep duration was about eight minutes, with uncertainty ranging from 23 fewer to 38 additional minutes. Quality of life might improve, but its estimate also allowed for no benefit or worsening. These findings remain very uncertain.
Cannabis may increase adverse events compared with placebo, based on three studies involving 98 participants and low-certainty evidence. The pooled odds ratio was 11.25, but this does not mean everyone faces an elevenfold increase in absolute risk; the authors described the increase as slight. These findings support caution about using cannabis as an established insomnia treatment. Patients and clinicians should discuss uncertain benefits, possible harms, and alternative approaches before treatment.
Confidence in benefit estimates was very low, and confidence in adverse event evidence was low. High risk of bias, inconsistent results, and imprecise estimates limit interpretation. Different preparations also complicate applying results to individual products. Larger, well-designed trials with longer follow-up are needed to clarify effectiveness and safety. This summary uses only the abstract; detailed methods and complete individual study results were unavailable.
Key Findings
- Nine randomized studies involving 537 adults did not establish clinically meaningful improvements in sleep quality, sleep duration, or daytime functioning.
- Estimated sleep duration increased by 7.68 minutes; the confidence interval ranged from 23.04 fewer to 38.39 additional minutes.
- Adverse events were more likely with cannabis in three studies involving 98 participants, but evidence certainty was low.
- Possible quality of life benefits remain uncertain; the confidence interval included no benefit and worsening.
- Discuss uncertain benefits and potential harms with a clinician rather than assuming medical cannabis is an established insomnia treatment.
Methodology
This Cochrane systematic review included nine randomized trials and searched multiple databases and two trial registers through April 5, 2025. Researchers used random-effects meta-analysis where possible, Cochrane risk-of-bias tools, and GRADE to assess evidence certainty for selected outcomes against placebo.
Study Limitations
This summary is based on the abstract only; full methods, adverse-event details, and individual trial results were unavailable. Evidence was weakened by study bias, inconsistent findings, small samples, and differences between preparations. Long-term safety and applicability to more diverse populations remain uncertain.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: